Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communications in daily practice. We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician-patient communication points to facilitate shared decision-making.

Practical considerations in the use of regorafenib in metastatic colorectal cancer / Loupakis, Fotios; Antonuzzo, Lorenzo; Bachet, Jean-Baptiste; Kuan, Feng-Che; Macarulla, Teresa; Pietrantonio, Filippo; Xu, Rui-Hua; Taniguchi, Hiroya; Winder, Thomas; Yuki, Satoshi; Zeng, Shan; Bekaii-Saab, Tanios. - In: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. - ISSN 1758-8340. - STAMPA. - 12:(2020), pp. 175883592095686.1-175883592095686.12. [10.1177/1758835920956862]

Practical considerations in the use of regorafenib in metastatic colorectal cancer

Antonuzzo, Lorenzo;
2020

Abstract

Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communications in daily practice. We discuss the importance of appropriate patient selection and adverse events management through close patient monitoring and dose adjustments to ensure patients stay on treatment for longer and receive as much benefit as possible. We also highlight key physician-patient communication points to facilitate shared decision-making.
12
1
12
Loupakis, Fotios; Antonuzzo, Lorenzo; Bachet, Jean-Baptiste; Kuan, Feng-Che; Macarulla, Teresa; Pietrantonio, Filippo; Xu, Rui-Hua; Taniguchi, Hiroya; Winder, Thomas; Yuki, Satoshi; Zeng, Shan; Bekaii-Saab, Tanios
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1287137
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact